Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NANP | Q8TBE9 | 3/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | SELL | P14151 | 1/20 | 0.33 |
| ▸ | SELP | P16109 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | MAG | P20916 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13190998 | 1.00 | NANP (0.59) | NANPL3MBTL1TDP1SELLSELP | |
| SCHEMBL29569418 | 1.00 | NANP (0.59) | NANPL3MBTL1TDP1SELLSELP | |
| SCHEMBL28733265 | 1.00 | NANP (0.59) | NANPL3MBTL1TDP1SELLSELP | |
| SCHEMBL28733258 | 0.92 | NANP (0.62) | NANPL3MBTL1SELLSELPMAG | |
| SCHEMBL29462899 | 0.92 | NANP (0.62) | NANPL3MBTL1SELLSELPMAG | |
| SCHEMBL6046356 | 0.92 | NANP (0.62) | NANPL3MBTL1SELLSELPMAG | |
| SCHEMBL13410073 | 0.91 | NANP (0.49) | NANPL3MBTL1MAG | |
| SCHEMBL28733256 | 0.91 | NANP (0.49) | NANPL3MBTL1MAG | |
| SCHEMBL29570167 | 0.91 | NANP (0.49) | NANPL3MBTL1MAG | |
| SCHEMBL6046360 | 0.91 | NANP (0.49) | NANPL3MBTL1MAG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220288095-A1 | SIALIC ACID FOR USE IN THE TREATMENT OF PSORIASIS | LIFESCIENCE AS (NO) | 2022-09-15 | — | — | US | claimed |
| EP-4003365-A1 | SIALIC ACID FOR USE IN THE TREATMENT OF PSORIASIS | Lifescience AS (NO) | 2022-06-01 | — | — | EP | claimed |
| WO-2021019295-A1 | SIALIC ACID FOR USE IN THE TREATMENT OF PSORIASIS | REMMEREIT JAN (NO) | 2021-02-04 | — | — | WO | claimed |
| EP-0524143-B1 | Process of preparation of activated sialic acids | CIBA GEIGY AG (CH) | 1997-12-10 | — | — | EP | claimed |
| US-5334514-A | Reacting sialic acid with cytidine 5*-triphosphate in presence of cell extract of microorganism having cytidine 5*-monophospho-N-acetylneuraminic acid synthetase activity | CIBA VISION CORPORATION | 1994-08-02 | — | — | US | claimed |
| EP-0524143-A1 | Process of preparation of activated sialic acids | CIBA-GEIGY AG (CH) | 1993-01-20 | — | — | EP | claimed |
| EP-4742902-A1 | METHOD TO IMPROVE A PLANT'S GROWTH, DEVELOPMENT AND RESISTANCE TO (A)BIOTIC STRESS | Globachem NV (BE) | 2026-05-20 | — | — | EP | disclosed |
| EP-4742901-A1 | METHOD TO IMPROVE A PLANT'S GROWTH, DEVELOPMENT AND RESISTANCE TO (A)BIOTIC STRESS | Globachem NV (BE) | 2026-05-20 | — | — | EP | disclosed |
| EP-4742899-A1 | METHOD TO IMPROVE A PLANT'S GROWTH, DEVELOPMENT AND RESISTANCE TO (A)BIOTIC STRESS | Globachem NV (BE) | 2026-05-20 | — | — | EP | disclosed |
| EP-4743567-A1 | CELLULAR PRODUCTION OF LACTO-N-TRIOSE (LN3)-CONTAINING OLIGOSACCHARIDES | Inbiose N.V. (BE) | 2026-05-20 | — | — | EP | disclosed |
| EP-4742900-A1 | METHOD TO IMPROVE A PLANT'S GROWTH, DEVELOPMENT AND RESISTANCE TO (A)BIOTIC STRESS | Globachem NV (BE) | 2026-05-20 | — | — | EP | disclosed |
| US-20260083762-A1 | SIALIC ACID COMPOSITIONS FOR THE USE OF INHIBITING AND TREATING CORONAVIRUS INFECTION | LIFESCIENCE AS (NO) | 2026-03-26 | — | — | US | disclosed |
| US-12390481-B2 | Sialic acid compositions for the use of inhibiting and treating coronavirus infection | LIFESCIENCE AS (NO) | 2025-08-19 | — | — | US | disclosed |
| EP-0839042-A1 | BACTERIAL INHIBITION WITH AN OLIGOSACCHARIDE COMPOUND | Neose Technologies, Inc. (US) | 1998-05-06 | — | — | EP | disclosed |
| US-5736533-A | INHIBITING COLONIZATION OF STREPTOCOCCUS PNEUMONIAE, HEMOPHILUS INFLUENZA OR PARAINFLUENZA, BURKHOLDERIA (PSEUDOMONAS) CEPACIA BY ADMINISTERING BINDING INHIBITING OLIGOSACCHARIDE | NEOSE TECHNOLOGIES, INC. (US) | 1998-04-07 | — | — | US | disclosed |
| EP-0524143-B1 | Process of preparation of activated sialic acids | CIBA GEIGY AG (CH) | 1997-12-10 | — | — | EP | disclosed |
| WO-1997041875-A1 | BISMUTH SALT OF SIALYLOLIGOSACCHARIDE AND A METHOD FOR TREATING AND INHIBITING GASTRIC AND DUODENAL ULCERS WITH SAME | NEOSE TECHNOLOGIES, INC. (US) | 1997-11-13 | — | — | WO | disclosed |
| WO-1996040169-A1 | BACTERIAL INHIBITION WITH AN OLIGOSACCHARIDE COMPOUND | NEOSE TECHNOLOGIES, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| US-5334514-A | Reacting sialic acid with cytidine 5*-triphosphate in presence of cell extract of microorganism having cytidine 5*-monophospho-N-acetylneuraminic acid synthetase activity | CIBA VISION CORPORATION | 1994-08-02 | — | — | US | disclosed |
| EP-0524143-A1 | Process of preparation of activated sialic acids | CIBA-GEIGY AG (CH) | 1993-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260083762-A1 | SIALIC ACID COMPOSITIONS FOR THE USE OF INHIBITING AND TREATING CORONAVIRUS INFECTION | NEU2, NEU1, SIGLEC9 | NANP 32/4885L3MBTL1 4162/4885TDP1 3727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.